抗体偶联药物(ADC)近年来实现快速发展,有数据预测,到2028年,全球ADC市场规模将接近300亿美元,年复合增长率将保持在20%以上。面对广阔的市场,药企加紧布局,有数据统计,全球范围内已有超过30款ADC管线挺进III期临床或上市申报阶段。如恒瑞医药有多款ADC药物进入临床三期。如SHR-A1811,是一款HER2靶向ADC,该产品已多次被中国国家药监局药品审评中心(CDE)纳入突破性治疗...
Source Link抗体偶联药物(ADC)近年来实现快速发展,有数据预测,到2028年,全球ADC市场规模将接近300亿美元,年复合增长率将保持在20%以上。面对广阔的市场,药企加紧布局,有数据统计,全球范围内已有超过30款ADC管线挺进III期临床或上市申报阶段。如恒瑞医药有多款ADC药物进入临床三期。如SHR-A1811,是一款HER2靶向ADC,该产品已多次被中国国家药监局药品审评中心(CDE)纳入突破性治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.